All lobbying filings

MERCK & CO, INC.

MERCK & CO, INC. filed a Q1 report for MERCK & CO INC on April 20, 2026.

Lobbying for MERCK & CO INC

All filings by MERCK & CO, INC. · Everything MERCK & CO INC has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$4,150,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals.

Medicare/Medicaid

Issues relating to, One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Cost and value of medicines: Drug pricing and reimbursement issues; FY-2027 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP).

Taxation/Internal Revenue Code

Issues relating to, Tax reform and tax policy, generally; Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes; Tax Cuts and Jobs Act (P.L. 115-97), provisions relating to tax reform.

Animals

Issues relating to, Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Agriculture, Rural Development , Food and Drug Administration, and Related Agencies Appropriations Bill, 2026; Commerce, Justice, Science, and Related Agencies Appropriations Bill, 2026; Interior, Environment, and Related Agencies Appropriations Bill 2026.

Bills named in this filing 2

S. 1339
Pharmacy Benefit Manager Reform Act
S. 2076
PASTEUR Act of 2021

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.